Lonza will invest approximately CHF 650 million to build new state-of-the-art facilities on its Visp site, in the canton of Valais. This new investment will allow the company to better respond to customer demand regarding capacity, life cycle management and speed to market.
This new expansion will allow the creation of "large-scale" cell production lines, adding six 20,000-liter bioreactors to meet the to meet the increasing market demand for biologics.
The new facility will have an area of approximately 27,500 square meters, and will increase large-scale biologics manufacturing. This state-of-the-art, high throughput facility will include perfusion capabilities and is designed to support high titer processes and accommodate the next generation of mammalian biologics.
Engineered to optimize energy efficiency and water use, the facility is expected to be completed in 2024 and will require an investment of approximately CHF 650 million. More than 300 new jobs will be created in Visp.
This new expansion will complement the existing large-scale global network at Lonza sites in Tuas (SG), Portsmouth (US) and Porriño (ES), and follows Lonza’s recent construction of a new manufacturing facility dedicated to small molecules, new production lines for the manufacture of antibody-drug conjugates and a new building dedicated to the production of Moderna's Covid-19 vaccine.